Michael W. Nall - 02 Sep 2021 Form 4 Insider Report for BIOCEPT INC

Reporting relationship: CEO & President, Director
Issuer ticker: N/A
Reported as of: 02 Sep 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Sep 2021, 21:56:58 UTC
Source filing: View source filing
Reporting owner signature: /s/ Michael W. Nall

Key filing fact

Michael W. Nall filed Form 4 for BIOCEPT INC on 02 Sep 2021.

Key facts

This page summarizes Michael W. Nall's Form 4 filing for BIOCEPT INC.
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Sep 2021, 21:56.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIOC transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 02 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $3.76
Footnotes: F1

BIOC transaction Derivative

Performance-Based Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +80,000
Change %
Price: $0.000000
Shares after: 80,000
Date: 02 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $3.76
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

1/36th of the shares subject to the option shall vest monthly following the Vesting Commencement Date of 9/2/21 until fully vested on 9/2/2024.

Footnote F2

1/36th of the shares subject to the option shall vest monthly, commencing upon the Issuer's achievement of a specified corporate milestone.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .